OSE Immunotherapeutics Unveils 2026 Financial Calendar

OSE Immunotherapeutics SA has released its financial calendar for 2026. The biotech company, specializing in immuno-oncology and immuno-inflammation, will report its 2025 full-year financial update on April 29, 2026. The 1Q 2026 cash position follows on April 30. Shareholders can anticipate the Annual General Meeting on June 24, 2026.

The first-half financial results are scheduled for September 28, while the 3Q cash position will be announced on October 27. Closing out the year, the 4Q cash position is set for January 26, 2027. The company advises that these dates may change.

OSE, listed on Euronext, works with academic and biopharmaceutical partners to develop innovative treatments. The detailed financial calendar can be accessed on its corporate website.